Article info

Original research
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study

Authors

  1. Correspondence to Dr Jacob N Hunnicutt; jacob.n.hunnicutt{at}gsk.com
View Full Text

Citation

Hunnicutt JN, Fairburn-Beech J, Georgiou ME, et al
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study

Publication history

  • Received April 4, 2022
  • Accepted October 23, 2022
  • First published November 30, 2022.
Online issue publication 
November 30, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.